Navigation Links
VG2 PLIF Allograft

ProductsVG2 PLIF Allograft
Company DePuy Orthopaedics, Inc.
Item VG2 PLIF Allograft
Features Cortical and cancellous bone provides structural strength and excellent osteoconductive environment. VG2 PLIF Allograft is available in parallel and trapezoid shapes for proper sagittal alignment of the lumbar spine.
Description VG2 PLIF Allograft is comprised of two cortical planks of bone surrounding a cancellous center. The cortical planks provide strength for anterior column support. The cancellous bone provides a lattice for remodeling, ensuring an excellent osteoconductive environment. Superior and inferior surface teeth increase the stability of the graft and resist graft migration.
Info DePuy Orthopaedics, Inc.
Customer Service: (800) 366-8143

Related medicine products :

1. IBS® Allograft Lumbar
2. Connect Cervical Allografts System
3. Puros Allografts
4. VG1 ALIF Allograft
5. Corlok Lumbar Allograft System
6. Duet Lumbar Allograft System
7. Solo Lumbar Allograft System
8. Coreograft PLIF Allograft System
9. Bard Dermal Allograft
10. FasLata® Allograft Tissue
11. Bard® Dermal Allograft
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With Tubular Base.
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With Tubular Base.
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base.
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With Tubular Base.
Medicine Products:
(Date:1/8/2009)... may not be accurate in some cases , , T...rom the United States and the Netherlands, questio...ramingham Risk Score in predicting heart disease a..., based on findings of a decades-long study in tha...s risk on the basis of seven factors: age, gender,...
(Date:1/8/2009)...released this week showing that a growing number o...seases shines a much-needed spotlight on the need ...ocuses on primary and secondary prevention, accord...ease prevention. , , (Logo: http://www.news..., The study, conducted by Social & Scientific...
(Date:1/8/2009)... of cancer cells are keys to the development of a ...e spread of certain types of cancers called carcin...lung, among others. Armed with a new two-year gra...ch, an Illinois-based philanthropic foundation, im... co-workers at the Moores Cancer Center at the Uni...
(Date:1/8/2009)...ew treatments for secondary pneumonia , , MEMPH...tists at St. Jude Children,s Research Hospital hav...erial pneumonia following influenza. They found th...hich kill bacteria by inhibiting their protein syn...ine treatment with the "beta-lactam" antibiotic am...
Breaking Medicine News(10 mins):Health News:Studies Challenge Framingham Risk Score 2Health News:Studies Challenge Framingham Risk Score 3Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2Health News:Novel prostate cancer vaccine taking aim at cancer cell 'sweet spot' 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3
...tific review of a dozen patients who have received...gene therapy technique is safe and may be effectiv... disease. The patients, half of whom live on Long...illness and were no longer responding to medicines...
...ty scientists have claimed that they can trace mar...to determine whether it was grown indoors or out .... facility, the researchers hope to have something ... could tell police where and under what conditions...
... a free bird on June 26, after spending 23 days in...the Los Angeles County Sheriff's Department's Inma...' release was however not disclosed. Although her ...as for 45 days, authorities have said that 22 days...
...s have begun the first phase of human clinical tri...signed in-house. The drug is based on an inhibit...rsity. The researchers say that it may help interc...ease at an early stage. "Millions of people suffe...
Other Medicine News:Health News:Gene Therapy for Parkinsons Disease 2Health News:Now, It's Possible to Trace Marijuana to Its Roots 2Health News:Ex-IITian-designed Alzheimer's Drug's Human Clinical Trials Begin 2
(Date:1/7/2009)...Puhua Hospital Stem Cells Center ( http://www.stem...em cells to effectively treat neurological disorde...dditions to its medical and research staff that si...lities for growing numbers of incoming internation...stinguished Dr. Jiang Ping, who was named Chief Sc...
(Date:1/6/2009)... -- The Michael J. Fox Foundation awarded a total ...ams for pre-clinical research on potential new tre...g was awarded under the Foundation,s Therapeutics...ched in 2006, supports and bolsters industry-focus...of MJFF,s focus on ,de-risking, preclinical PD r...
(Date:1/5/2009)... Pharmaceuticals announced today that it has initi...ein kinase inhibitor, CX-4945, in patients with ad...ple myeloma. The primary endpoints of the oral dos...lerance and PK properties of CX-4945 and to select...tion, multiple mechanism-related pharmacodynamic b...
(Date:12/29/2008)...swire/ -- The winner of the 2008 Award for Excelle...ay by Dr. Peter G. Goldschmidt, President and Foun...he winner of the annual award was the Universit...ts best practice " IND Regulatory and Monitoring P...man subjects protection, 2) improved data quality ...
Breaking Medicine Technology:Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 32008 Human Research Protection Award Recipients Announced 2Institute for Integrative Nutrition Joshua Rosenthal Attract Nations Top Health Wellness Experts 11772 1Institute for Integrative Nutrition Joshua Rosenthal Attract Nations Top Health Wellness Experts 11772 2Institute for Integrative Nutrition Joshua Rosenthal Attract Nations Top Health Wellness Experts 11772 3Winner Medical Reports First Quarter Fiscal 2008 Results 11770 1Winner Medical Reports First Quarter Fiscal 2008 Results 11770 2Winner Medical Reports First Quarter Fiscal 2008 Results 11770 3Winner Medical Reports First Quarter Fiscal 2008 Results 11770 4Winner Medical Reports First Quarter Fiscal 2008 Results 11770 5Winner Medical Reports First Quarter Fiscal 2008 Results 11770 6Winner Medical Reports First Quarter Fiscal 2008 Results 11770 7Winner Medical Reports First Quarter Fiscal 2008 Results 11770 8Winner Medical Reports First Quarter Fiscal 2008 Results 11770 9Elsevier Foundation Announces Grants for Innovative Libraries and New Scholars 11768 1Elsevier Foundation Announces Grants for Innovative Libraries and New Scholars 11768 2Elsevier Foundation Announces Grants for Innovative Libraries and New Scholars 11768 3GeneGo Collaborates With The Netherlands Toxicogenomics Center on 24100 Million Grant 3253 1GeneGo Collaborates With The Netherlands Toxicogenomics Center on 24100 Million Grant 3253 2
...rstCall/--,EntreMed, Inc. , a clinical-stage pharm...treatment of cancer and inflammatory diseases,tod...ts for MKC-1,its novel cell cycle inhibitor. The ...American Association for Cancer Research (AACR),An...California. , MKC-1 is a novel, orally-active cell...
...ansurethral Resection,is Well Tolerated in Phase 2...2007 /PRNewswire-FirstCall/ --,Spectrum Pharmaceut... study of EOquin, in non-invasive bladder cancer a...L)-1620 and satraplatin,at the annual meeting of t...t the Los Angeles Convention Center in Los Angeles...
Other Medicine Technology:EntreMed Presents Preclinical Data for MKC-1 in Hematological,Cancers 2EntreMed Presents Preclinical Data for MKC-1 in Hematological,Cancers 3EntreMed Presents Preclinical Data for MKC-1 in Hematological,Cancers 4Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 2Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 3Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 4Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 5Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 6Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 7Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 8